CN106519205A - 一种载药多孔phbv接枝多巴胺微球的制备方法及应用 - Google Patents
一种载药多孔phbv接枝多巴胺微球的制备方法及应用 Download PDFInfo
- Publication number
- CN106519205A CN106519205A CN201610946617.1A CN201610946617A CN106519205A CN 106519205 A CN106519205 A CN 106519205A CN 201610946617 A CN201610946617 A CN 201610946617A CN 106519205 A CN106519205 A CN 106519205A
- Authority
- CN
- China
- Prior art keywords
- phbv
- porous
- dopa
- preparation
- dopamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000520 poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Polymers 0.000 title claims abstract description 78
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title claims abstract description 66
- 229960003638 dopamine Drugs 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 238000011068 loading method Methods 0.000 title abstract description 4
- 239000011859 microparticle Substances 0.000 title abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 20
- 229960004502 levodopa Drugs 0.000 claims abstract description 19
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 238000004108 freeze drying Methods 0.000 claims abstract description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000001301 oxygen Substances 0.000 claims abstract description 12
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 12
- 239000004005 microsphere Substances 0.000 claims description 57
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 230000000844 anti-bacterial effect Effects 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 229940088710 antibiotic agent Drugs 0.000 claims description 9
- 238000000520 microinjection Methods 0.000 claims description 9
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 6
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 claims description 6
- 238000009832 plasma treatment Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 3
- 230000008439 repair process Effects 0.000 claims description 3
- 108010059993 Vancomycin Proteins 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 2
- 229960003165 vancomycin Drugs 0.000 claims description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 abstract description 6
- 230000000845 anti-microbial effect Effects 0.000 abstract description 3
- 238000009833 condensation Methods 0.000 abstract description 2
- 230000005494 condensation Effects 0.000 abstract description 2
- 229940124350 antibacterial drug Drugs 0.000 abstract 1
- 230000021523 carboxylation Effects 0.000 abstract 1
- 238000006473 carboxylation reaction Methods 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002188 osteogenic effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229920001634 Copolyester Polymers 0.000 description 1
- -1 acacatechin amine Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/91—Polymers modified by chemical after-treatment
- C08G63/912—Polymers modified by chemical after-treatment derived from hydroxycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/12—Powdering or granulating
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/28—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/36—After-treatment
- C08J9/40—Impregnation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2201/00—Foams characterised by the foaming process
- C08J2201/04—Foams characterised by the foaming process characterised by the elimination of a liquid or solid component, e.g. precipitation, leaching out, evaporation
- C08J2201/048—Elimination of a frozen liquid phase
- C08J2201/0482—Elimination of a frozen liquid phase the liquid phase being organic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
- C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种载药多孔PHBV接枝多巴胺微球的制备方法及应用，步骤如下：利用氧等离子体技术使PHBV表面羧基化，得到PHBV‑COOH；将多巴胺偶联到PHBV‑COOH的表面，得到多巴胺修饰的PHBV，即PHBV‑DOPA；利用静电液滴冷凝法制备PHBV‑DOPA微球，然后利用冷冻干燥法制备PHBV‑DOPA多孔微球；利用冷冻干燥法将抗菌药物吸附在PHBV‑DOPA多孔微球的孔隙中，得到载药多孔PHBV‑DOPA微球。本发明有效的提高了PHBV的生物活性，同时提高了PHBV的抗菌性能，且本发明制备工艺简单，反应条件温和，有效的拓宽了PHBV的应用范围。
Description
技术领域
本发明涉及一种药物载体及组织工程材料的制备方法及其应用，属于医用高分子领域，具体涉及一种载药多孔PHBV接枝多巴胺微球的新的制备方法及应用。
背景技术
聚羟基丁酸戊酸共聚酯（PHBV）是细菌在不平衡生长的条件下储存在细胞内的一种不溶于水的高分子聚合物，具有生物可降解性，无抗原性且无毒，无致癌性，生物相容性良好，近年来受到广泛关注。
同时，PHBV在医药领域具有较为广阔的应用前景，例如：将其用作手术缝合线的基材、骨骼和血管的替代品以及用作药物缓释的载体等。鉴于PHBV对人体无任何的副作用，因此将PHBV作为药物缓释载体作为骨组织工程修复材料已经引起了国外研究者的极大的兴趣。目前，PHBV载药的手段主要是将其制作成多孔微球，将药物负载到PHBV微球的孔隙中，从而达到药物的缓释。目前PHBV微球的制备方法主要有溶剂蒸发法，这种方法制备的微球粒径较小，不能够作为骨组织工程支架，且这种方法会残留有机溶剂对人体产伤害。此外，PHBV虽然本身具有较好的生物相容性，但是其本身活性较差，因而需要对其进行改性，以增加其生物活性。
多巴胺是一种低分子量类儿茶酚胺，多巴胺具有优异的亲水性、细胞亲和性以及良好的成骨活性，有效弥补生物降解聚酯亲水性和细胞亲和性差、缺乏成骨活性等不足，赋予复合材料良好的生物功能性。
发明内容
本发明的目的在于提供一种载药多孔PHBV接枝多巴胺微球的制备方法，主要是为了解决PHBV生物活性较差，以及弥补目前PHBV多孔载药微球在制备方法上的一些不足。本发明的反应基本上是在常温下进行，且反应条件温和，制备效率较高。同时本发明所制备的微球具有良好的生物活性和抗菌性能，特别适用于骨组织工程方面的应用。
为解决上述技术问题，本发明采用以下技术方案：
一种载药多孔PHBV接枝多巴胺微球的制备方法，步骤如下：
（1）将PHBV粉末放入氧等离子处理器中，利用氧等离子体技术使PHBV表面羧基化，得到表面羧基化的PHBV（PHBV-COOH）；
（2）将步骤（1）得到的表面羧基化的PHBV进行干燥，然后将干燥后的表面羧基化的PHBV溶于二氯甲烷溶液中，加入N,N'-羰基二咪唑，对表面羧基化的PHBV上的羧基进行活化1h，然后加入多巴胺，搅拌反应8h，反应结束后将沉淀洗涤，干燥，得到多巴胺修饰的PHBV（PHBV-DOPA）；
（3）将多巴胺修饰的PHBV（PHBV-DOPA）溶于二氯甲烷溶液中，然后利用微量注射泵将其缓慢注射到液氮中，同时在微量注射泵的针头上施加电压，将得到的PHBV-DOPA微球进行冷冻干燥，得到PHBV-DOPA多孔微球；
（4）利用冷冻干燥法将抗菌药物吸附在PHBV-DOPA多孔微球的孔隙中，得到载药多孔PHBV接枝多巴胺微球。
所述步骤（1）利用氧等离子体技术使PHBV表面羧基化时，等离子体处理器的功率为200-300W，压力为20-30Pa，处理时间为5-40min。
所述步骤（2）中表面羧基化的PHBV与N,N'-羰基二咪唑的物质的量之比为1:2-5，多巴胺与表面羧基化的PHBV的物质的量之比为1-2:1。
所述步骤（3）中施加在注射器针头上的电压为5-20kV，注射速率为30-60mL/h。
所述步骤（4）中的抗菌药物的质量为PHBV-DOPA多孔微球质量的1-5%。
所述步骤（4）中的抗菌药物包括但不限于万古霉素或布洛芬。
利用所述的载药多孔PHBV接枝多巴胺微球的制备方法制得的载药多孔PHBV接枝多巴胺微球用于组织工程支架修复组织损伤以及抑制组织发生感染。
本发明的有益效果：1、本发明通过表面改性的方法提高了PHBV本身的亲水性、细胞亲和性以及良好的成骨活性，改善了PHBV本身的生物活性不足的问题；2、本发明所采用的多孔载药微球的制备方法较为简单，微球的大小可调，制备效率较高，且不存在溶剂残留的问题；3、本发明中的多孔微球载药的方法为冷冻干燥法，有效的保留了药物的活性，能够起到较好的抑菌效果，提高了PHBV的抗菌性能；4、本发明所制备的载药多孔微球有效的抑制了抗菌药物在人体中释放过快的问题，提高了药物的利用率，同时延长了抑菌时间；5、本发明将多巴胺修饰在PHBV的表面，改善了PHBV的生物活性，然后利用静电液滴冷凝法制备了PHBV多孔微球，制备方法较为简单，反应条件温和，有效的拓宽了PHBV的应用范围，具有良好的应用前景。
具体实施方式
下面结合具体实施例，对本发明做进一步说明。应理解，以下实施例仅用于说明本发明而非用于限制本发明的范围，该领域的技术熟练人员可以根据上述发明的内容作出一些非本质的改进和调整。
实施例1
本实施例的载药多孔PHBV接枝多巴胺微球的制备方法，步骤如下：
（1）将10g PHBV粉末放入氧等离子处理器中抽真空至7Pa，后通入氨气至20Pa，在200W强度下处理5min，然后将处理后的PHBV材料清洗、干燥，即得到羧基化的PHBV（PHBV-COOH）；
（2）将PHBV-COOH在50℃条件下真空干燥8h，然后将将1g（0.015mol）无水PHBV-COOH溶于100mL二氯甲烷溶液中，然后加入4.75g （0.03mol）N,N'-羰基二咪唑，对羧基进行活化1h，然后将1.64g多巴胺（0.015mol）加入到PHBV-COOH溶液中，搅拌反应8h即得到PHBV-DOPA，反应结束后将PHBV-DOPA沉淀，洗涤，干燥；
（3）将10gPHBV-DOPA溶于100mL二氯甲烷溶液中，然后利用微量注射泵以30mL/h的速率将其缓慢注射到液氮中，同时在注射器的针头上施加5kV的电压，将得到的PHBV-DOPA微球进行冷冻干燥法即可得到多孔微球；
（4）将0.1g万古霉素溶于水中，然后将10g多孔PHBV-DOPA微球浸泡到药液中，然后将多孔微球冷冻干燥，即得到载药多孔PHBV-DOPA微球。
实施例2
本实施例的载药多孔PHBV接枝多巴胺微球的制备方法，步骤如下：
（1）将10g PHBV粉末放入氧等离子处理器中抽真空至7Pa，后通入氨气至30Pa，在300W强度下处理40min，然后将处理后的PHBV材料清洗、干燥，即得到羧基化的PHBV（PHBV-COOH）；
（2）将1g（0.015mol）无水PHBV-COOH溶于100mL二氯甲烷溶液中，然后加入12.15g（0.075mol） N,N'-羰基二咪唑，对羧基进行活化1h，然后将3.28g（0.03mol）多巴胺加入到PHBV-COOH溶液中，搅拌反应8h即得到PHBV-DOPA，反应结束后将PHBV-DOPA沉淀，洗涤，干燥；
（3）将10gPHBV-DOPA溶于100mL二氯甲烷溶液中，然后利用微量注射泵以60mL/h的速率将其缓慢注射到液氮中，同时在注射器的针头上施加20kV的电压，将得到的PHBV-DOPA微球进行冷冻干燥法即可得到多孔微球；
（4）将0.5g布洛芬溶于水中，然后将10g多孔PHBV-DOPA微球浸泡到药液中，然后将多孔微球冷冻干燥，即得到载药多孔PHBV-DOPA微球。
实施例3
本实施例的载药多孔PHBV接枝多巴胺微球的制备方法，步骤如下：
（1）将10g PHBV粉末放入氧等离子处理器中抽真空至7Pa，后通入氨气至20Pa，在200W强度下处理25min，然后将处理后的PHBV材料清洗、干燥，即得到羧基化的PHBV；
（2）将1g（0.015mol）无水PHBV-COOH溶于100mL二氯甲烷溶液中，然后加入9.50g（0.06mol）N,N'-羰基二咪唑，对羧基进行活化1h，然后将1.64g（0.015mol）多巴胺加入到PHBV-COOH溶液中，搅拌反应8h即得到PHBV-DOPA，反应结束后将PHBV-DOPA沉淀，洗涤，干燥；
（3）将10gPHBV-DOPA溶于100mL二氯甲烷溶液中，然后利用微量注射泵以40mL/h的速率将其缓慢注射到液氮中，同时在注射器的针头上施加10kV的电压，将得到的PHBV-DOPA微球进行冷冻干燥法即可得到多孔微球；
（4）将0.3g抗菌药物溶于水中，然后将10g多孔PHBV-DOPA微球浸泡到药液中，然后将多孔微球冷冻干燥，即得到载药多孔PHBV-DOPA微球。
实施例4
本实施例的载药多孔PHBV接枝多巴胺微球的制备方法，步骤如下：
（1）将10g PHBV粉末放入氧等离子处理器中抽真空至7Pa，后通入氨气至25Pa，在250W强度下处理20min，然后将处理后的PHBV材料清洗、干燥，即得到羧基化的PHBV（PHBV-COOH）；
（2）将1g（0.015mol）无水PHBV-COOH溶于100mL二氯甲烷溶液中，然后加入7.12g（0.045mol） N,N'-羰基二咪唑，对羧基进行活化1h，然后将2.46g（0.0225mol）多巴胺加入到PHBV-COOH溶液中，搅拌反应8h即得到PHBV-DOPA，反应结束后将PHBV-DOPA沉淀，洗涤，干燥；
（3）将10gPHBV-DOPA溶于100mL二氯甲烷溶液中，然后利用微量注射泵以50mL/h的速率将其缓慢注射到液氮中，同时在注射器的针头上施加20kV的电压，将得到的PHBV-DOPA微球进行冷冻干燥法即可得到多孔微球；
（4）将0.5g抗菌药物溶于水中，然后将10g多孔PHBV-DOPA微球浸泡到药液中，然后将多孔微球冷冻干燥，即得到载药多孔PHBV-DOPA微球。
以上显示和描述了本发明的基本原理和主要特征以及本发明的优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的原理，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (7)
1.一种载药多孔PHBV接枝多巴胺微球的制备方法，其特征在于步骤如下：
（1）将PHBV粉末放入氧等离子处理器中，利用氧等离子体技术使PHBV表面羧基化，得到表面羧基化的PHBV；
（2）将步骤（1）得到的表面羧基化的PHBV进行干燥，然后将干燥后的表面羧基化的PHBV溶于二氯甲烷溶液中，加入N,N'-羰基二咪唑，对表面羧基化的PHBV上的羧基进行活化1h，然后加入多巴胺，搅拌反应8h，反应结束后将沉淀洗涤，干燥，得到多巴胺修饰的PHBV；
（3）将多巴胺修饰的PHBV溶于二氯甲烷溶液中，然后利用微量注射泵将其缓慢注射到液氮中，同时在微量注射泵的针头上施加电压，将得到的PHBV-DOPA微球进行冷冻干燥，得到PHBV-DOPA多孔微球；
（4）利用冷冻干燥法将抗菌药物吸附在PHBV-DOPA多孔微球的孔隙中，得到载药多孔PHBV接枝多巴胺微球。
2.根据权利要求1所述的载药多孔PHBV接枝多巴胺微球的制备方法，其特征在于：所述步骤（1）利用氧等离子体技术使PHBV表面羧基化时，氧等离子体处理器的功率为200-300W，压力为20-30Pa，处理时间为5-40min。
3.根据权利要求1所述的载药多孔PHBV接枝多巴胺微球的制备方法，其特征在于：所述步骤（2）中表面羧基化的PHBV与N,N'-羰基二咪唑的物质的量之比为2-5:1，多巴胺与表面羧基化的PHBV的物质的量之比为1-2:1。
4.根据权利要求1所述的载药多孔PHBV接枝多巴胺微球的制备方法，其特征在于：所述步骤（3）中施加在微量注射泵针头上的电压为5-20kV，注射速率为30-60mL/h。
5.根据权利要求1所述的载药多孔PHBV接枝多巴胺微球的制备方法，其特征在于：所述步骤（4）中的抗菌药物的质量为PHBV-DOPA多孔微球质量的1-5%。
6.根据权利要求1所述的载药多孔PHBV接枝多巴胺微球的制备方法，其特征在于：所述步骤（4）中的抗菌药物包括但不限于万古霉素或布洛芬。
7.利用权利要求1~5任一所述的载药多孔PHBV接枝多巴胺微球的制备方法制得的载药多孔PHBV接枝多巴胺微球用于组织工程支架修复组织损伤以及抑制组织发生感染。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610946617.1A CN106519205B (zh) | 2016-10-26 | 2016-10-26 | 一种载药多孔phbv接枝多巴胺微球的制备方法及应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610946617.1A CN106519205B (zh) | 2016-10-26 | 2016-10-26 | 一种载药多孔phbv接枝多巴胺微球的制备方法及应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106519205A true CN106519205A (zh) | 2017-03-22 |
| CN106519205B CN106519205B (zh) | 2018-04-10 |
Family
ID=58292907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610946617.1A Expired - Fee Related CN106519205B (zh) | 2016-10-26 | 2016-10-26 | 一种载药多孔phbv接枝多巴胺微球的制备方法及应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106519205B (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106984290A (zh) * | 2017-06-02 | 2017-07-28 | 河南工程学院 | 可吸附重金属离子的壳聚糖/海藻酸钠磁性复合微球的制备方法 |
| CN113123016A (zh) * | 2021-03-05 | 2021-07-16 | 南京禾素时代抗菌材料科技有限公司 | 一种含phbv材料抗菌抗病毒phes热风无纺布的制备方法 |
| CN115772716A (zh) * | 2022-11-30 | 2023-03-10 | 新凤鸣集团湖州中石科技有限公司 | 一种弹性抗菌复合纤维及其制备方法 |
| CN115779134A (zh) * | 2022-11-17 | 2023-03-14 | 科睿驰（深圳）医疗科技发展有限公司 | 栓塞微球及其制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996000537A1 (en) * | 1994-06-29 | 1996-01-11 | Southern Research Institute | Microcapsules for administration of neuroactive agents |
| CN1762495A (zh) * | 2004-09-21 | 2006-04-26 | 山东绿叶制药有限公司 | 含有多巴胺受体激动剂类药物的长效缓释制剂及其制备工艺 |
| US20090162407A1 (en) * | 2007-12-20 | 2009-06-25 | Danielle Biggs | Process for preparing microparticles having a low residual solvent volume |
| CN102108130A (zh) * | 2011-02-14 | 2011-06-29 | 东南大学 | 疏水性医用高分子材料的表面生物功能化方法 |
| CN105727362A (zh) * | 2014-12-08 | 2016-07-06 | 中国科学院宁波材料技术与工程研究所 | 表层具有生物活性的组织工程材料及制备方法 |
-
2016
- 2016-10-26 CN CN201610946617.1A patent/CN106519205B/zh not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996000537A1 (en) * | 1994-06-29 | 1996-01-11 | Southern Research Institute | Microcapsules for administration of neuroactive agents |
| CN1762495A (zh) * | 2004-09-21 | 2006-04-26 | 山东绿叶制药有限公司 | 含有多巴胺受体激动剂类药物的长效缓释制剂及其制备工艺 |
| US20090162407A1 (en) * | 2007-12-20 | 2009-06-25 | Danielle Biggs | Process for preparing microparticles having a low residual solvent volume |
| CN102108130A (zh) * | 2011-02-14 | 2011-06-29 | 东南大学 | 疏水性医用高分子材料的表面生物功能化方法 |
| CN105727362A (zh) * | 2014-12-08 | 2016-07-06 | 中国科学院宁波材料技术与工程研究所 | 表层具有生物活性的组织工程材料及制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| B.M.P. FERREIRA，等: "Plasma surface treatments of poly(L-lactic acid) (PLLA) and poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV)", 《MATERIALS SCIENCE AND ENGINEERING C》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106984290A (zh) * | 2017-06-02 | 2017-07-28 | 河南工程学院 | 可吸附重金属离子的壳聚糖/海藻酸钠磁性复合微球的制备方法 |
| CN106984290B (zh) * | 2017-06-02 | 2020-01-07 | 河南工程学院 | 可吸附重金属离子的壳聚糖/海藻酸钠磁性复合微球的制备方法 |
| CN113123016A (zh) * | 2021-03-05 | 2021-07-16 | 南京禾素时代抗菌材料科技有限公司 | 一种含phbv材料抗菌抗病毒phes热风无纺布的制备方法 |
| CN115779134A (zh) * | 2022-11-17 | 2023-03-14 | 科睿驰（深圳）医疗科技发展有限公司 | 栓塞微球及其制备方法 |
| CN115772716A (zh) * | 2022-11-30 | 2023-03-10 | 新凤鸣集团湖州中石科技有限公司 | 一种弹性抗菌复合纤维及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106519205B (zh) | 2018-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | Electrospun fibers and their application in drug controlled release, biological dressings, tissue repair, and enzyme immobilization | |
| CN106519205B (zh) | 一种载药多孔phbv接枝多巴胺微球的制备方法及应用 | |
| Tahtat et al. | Oral delivery of insulin from alginate/chitosan crosslinked by glutaraldehyde | |
| Vasconcellos et al. | Production and characterization of chitosan microparticles containing papain for controlled release applications | |
| CN108653741B (zh) | 一种金属有机配位聚合物包裹的天然丝胶蛋白微球及其制备方法和应用 | |
| Nair et al. | Application of chitosan microspheres as drug carriers: a review | |
| CN101249077A (zh) | 一种可降解聚合物多孔微球的制备方法及其用途 | |
| Duan et al. | Polymeric nanofibers for drug delivery applications: a recent review | |
| CN101721739A (zh) | 可缓控释治疗性药物的高分子复合纤维手术缝合线及其制备方法 | |
| Maleki et al. | Nanofiber-based systems intended for diabetes | |
| WO2009054006A2 (en) | Biodegradable polymer scaffold and process for preparation thereof | |
| Thien | Electrospun chitosan/PVA nanofibers for drug delivery | |
| CN111671736B (zh) | 基于金属有机框架的药物载体及其制备方法和在口服药物载体中的应用 | |
| Rybak et al. | Injectable and self-healable nano-architectured hydrogel for NIR-light responsive chemo-and photothermal bacterial eradication | |
| Sun et al. | Rationally designed particle preloading method to improve protein delivery performance of electrospun polyester nanofibers | |
| CN104623721A (zh) | 一种创伤修复材料及其制备方法 | |
| Zhou et al. | Preparation and application of hemostatic hydrogels | |
| Nicolae et al. | Polymer fibers in biomedical engineering | |
| CN104434792A (zh) | 聚合物胶束及其制备方法和抗肿瘤药物组合物、制剂及其制备方法 | |
| Wang et al. | The effect of magnetic poly (lactic-co-glycolic acid) microsphere-gelatin hydrogel on the growth of pre-osteoblasts under static magnetic field | |
| CN102727946B (zh) | 一种载药涂层及其制备方法 | |
| CN109126648B (zh) | 一种壳聚糖和藻酸丙二醇酯共混微胶囊的制备及其应用 | |
| CN101491689B (zh) | 可生物降解复合超细纤维药物控制释放毡及其制备工艺 | |
| CN105919944A (zh) | 一种含凝胶内核的可降解聚合物微球及其制备方法和应用 | |
| Parin et al. | Electrospun porous biobased polymer mats for biomedical applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Yanwei Inventor after: Fan Lidan Inventor after: Delayed Dragon Inventor after: Xu Qian Inventor after: Zhang Hao Inventor after: Yu Xiang Inventor after: Wei Yuan Inventor after: Yang Xiuqin Inventor before: Wang Yanwei Inventor before: Yu Xiang Inventor before: Delayed Dragon Inventor before: Xu Qian Inventor before: Zhang Hao Inventor before: Wei Yuan Inventor before: Yang Xiuqin |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201126 Address after: 703, No. 49, Lane 825, Chenhui Road, Pudong New Area, Shanghai, 201203 Patentee after: Cui Wenhao Address before: 102400 No.18 Jianshe Road, Kaixuan street, Liangxiang, Fangshan District, Beijing Patentee before: Beijing nine Er Intellectual Property Service Co.,Ltd. Effective date of registration: 20201126 Address after: 102400 No.18 Jianshe Road, Kaixuan street, Liangxiang, Fangshan District, Beijing Patentee after: Beijing nine Er Intellectual Property Service Co.,Ltd. Address before: 451191 Zhongshan North Road, Henan, Xinzheng, Longhu Town, No. 1, Patentee before: HENAN INSTITUTE OF ENGINEERING |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210315 Address after: 518000 Room 202, building a11, life science and Technology Industrial Park, Kuiyong street, Dapeng New District, Shenzhen City, Guangdong Province Patentee after: Letu Youjia (Shenzhen) Pharmaceutical Technology Co.,Ltd. Address before: 703, No. 49, Lane 825, Chenhui Road, Pudong New Area, Shanghai, 201203 Patentee before: Cui Wenhao |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180410 Termination date: 20211026 |